UNITED THERAPEUTICS Corp
For the period ended Sep 30, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 30, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(c)Trading Plans
On August 2, 2024, Raymond Dwek, amember of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 10,000 stock options and sell the shares of common stock received, subject to certain conditions.
On August 7, 2024, trusts beneficially owned by Michael Benkowitz, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 201,679 stock options and sell the shares of common stock received, subject to certain conditions.
On August 27, 2024, Christopher Patusky, amember of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 10,000 stock options and sell the shares of common stock received, subject to certain conditions.
During the three months ended September 30, 2024, no director or Section 16 officer terminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).
| 56 | United Therapeutics, a public benefit corporation |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.